Bioengineered protein-based nanocage for drug delivery

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 157-171

  Lee, Eun Jung ^a   Lee, Na Kyeong ^a,b   Kim, In San ^a,c  

^a Korea Institute of Science and Technology   (South Korea)

^b Seoul National University   (South Korea)

^c Korea University   (South Korea)

Author keywords

Bioengineering; Cancer therapy; Drug delivery; Functionalization; Protein based nanocage

Indexed keywords

DRUG DELIVERY; MEDICINE; SYSTEMS SCIENCE;

CANCER THERAPY; CHEMICAL FUNCTIONALIZATION; CLINICAL APPLICATION; CRITICAL EVALUATION; DRUG DELIVERY CARRIER; FUNCTIONALIZATIONS; NANOCAGES; PROTEIN STRUCTURES;

PROTEINS;

DOXORUBICIN; FERRITIN; NANOCAGE; NANOMATERIAL; RIBONUCLEOPROTEIN; SMALL HEAT SHOCK PROTEIN; DRUG CARRIER; NANOPARTICLE; PROTEIN;

BIOENGINEERING; BROMOVIRIDAE; CANCER THERAPY; CELL PROLIFERATION; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CHEMICAL REACTION KINETICS; COVALENT BOND; COWPEA CHLOROTIC MOTTLE VIRUS; COWPEA MOSAIC VIRUS; CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENTEROBACTERIA PHAGE MS2; ENTEROBACTERIA PHAGE QBETA; GENE FUNCTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; REVIEW; STRUCTURE ANALYSIS; VIRUS LIKE AGENT; ANIMAL; CHEMISTRY;

ANIMALS; BIOENGINEERING; DRUG CARRIERS; HUMANS; NANOPARTICLES; PROTEINS;

EID: 84962128027     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.03.002     Document Type: Review

References (246)

1. [1] Doll, T.A., Raman, S., Dey, R., Burkhard, P., Nanoscale assemblies and their biomedical applications. J. R. Soc. Interface, 10, 2013, 20120740.
2. [2] Nune, S.K., Gunda, P., Thallapally, P.K., Lin, Y.-Y., Laird Forrest, M., Berkland, C.J., Nanoparticles for biomedical imaging. Expert Opin. Drug Deliv. 6 (2009), 1175–1194.
3. [3] Whitesides, G.M., The ‘right’ size in nanobiotechnology. Nat. Biotechnol. 21 (2003), 1161–1165.
4. [4] Deshayes, S., Gref, R., Synthetic and bioinspired cage nanoparticles for drug delivery. Nanomedicine 9 (2014), 1545–1564.
5. [5] Howorka, S., Rationally engineering natural protein assemblies in nanobiotechnology. Curr. Opin. Biotechnol. 22 (2011), 485–491.
6. [6] Pieters, B.J., van Eldijk, M.B., Nolte, R.J., Mecinovic, J., Natural supramolecular protein assemblies. Chem. Soc. Rev., 2015, 10.1039/C5CS00157A.
7. [7] Molino, N.M., Wang, S.W., Caged protein nanoparticles for drug delivery. Curr. Opin. Biotechnol. 28 (2014), 75–82.
8. [8] Herrera Estrada, L.P., Champion, J.A., Protein nanoparticles for therapeutic protein delivery. Biomater. Sci. 3 (2015), 787–799.
9. [9] Schoonen, L., van Hest, J.C., Functionalization of protein-based nanocages for drug delivery applications. Nanoscale 6 (2014), 7124–7141.
10. [10] Gao, J., Xu, B., Applications of nanomaterials inside cells. Nano Today 4 (2009), 37–51.
11. [11] Fakruddin, M., Hossain, Z., Afroz, H., Prospects and applications of nanobiotechnology: a medical perspective. J. Nanobiotechnol., 10, 2012, 31.
12. [12] Alyautdin, R., Tezikov, E., Ramge, P., Kharkevich, D., Begley, D., Kreuter, J., Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 15 (1998), 67–74.
13. [13] Garcia-Garcia, E., Gil, S., Andrieux, K., Desmaele, D., Nicolas, V., Taran, F., Georgin, D., Andreux, J., Roux, F., Couvreur, P., A relevant in vitro rat model for the evaluation of blood–brain barrier translocation of nanoparticles. Cell. Mol. Life Sci. 62 (2005), 1400–1408.
14. [14] Chakrabarti, S., Ruud, K., Intermolecular interaction-controlled tuning of the two-photon absorption of fullerene bound in a buckycatcher. J. Phys. Chem. A 113 (2009), 5485–5488.
15. [15] Meng, H., Xue, M., Xia, T., Ji, Z., Tarn, D.Y., Zink, J.I., Nel, A.E., Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 5 (2011), 4131–4144.
16. [16] Keereweer, S., Mol, I.M., Kerrebijn, J.D., Van Driel, P.B., Xie, B., de Jong, B., Robert, J., Vahrmeijer, A.L., Löwik, C.W., Targeting integrins and enhanced permeability and retention (EPR) effect for optical imaging of oral cancer. J. Surg. Oncol. 105 (2012), 714–718.
17. [17] Fang, J., Qin, H., Nakamura, H., Tsukigawa, K., Shin, T., Maeda, H., Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. Cancer Sci. 103 (2012), 535–541.
18. [18] Albanese, A., Tang, P.S., Chan, W.C., The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14 (2012), 1–16.
19. [19] Kim, R., Lai, L., Lee, H.-H., Cheong, G.-W., Kim, K.K., Wu, Z., Yokota, H., Marqusee, S., Kim, S.-H., On the mechanism of chaperone activity of the small heat-shock protein of Methanococcus jannaschii. Proc. Natl. Acad. Sci. 100 (2003), 8151–8155.
20. [20] Li, K., Zhang, Z.-P., Luo, M., Yu, X., Han, Y., Wei, H.-P., Cui, Z.-Q., Zhang, X.-E., Multifunctional ferritin cage nanostructures for fluorescence and MR imaging of tumor cells. Nanoscale 4 (2012), 188–193.
21. [21] Rome, L.H., Kickhoefer, V.A., Development of the vault particle as a platform technology. ACS Nano 7 (2012), 889–902.
22. [22] Annamalai, P., Apte, S., Wilkens, S., Rao, A., Deletion of highly conserved arginine-rich RNA binding motif in cowpea chlorotic mottle virus capsid protein results in virion structural alterations and RNA packaging constraints. J. Virol. 79 (2005), 3277–3288.
23. [23] Aljabali, A.A., Barclay, J.E., Steinmetz, N.F., Lomonossoff, G.P., Evans, D.J., Controlled immobilisation of active enzymes on the cowpea mosaic virus capsid. Nanoscale 4 (2012), 5640–5645.
24. [24] Hooker, J.M., Kovacs, E.W., Francis, M.B., Interior surface modification of bacteriophage MS2. J. Am. Chem. Soc. 126 (2004), 3718–3719.
25. [25] Pimentel, T.A., Yan, Z., Jeffers, S.A., Holmes, K.V., Hodges, R.S., Burkhard, P., Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem. Biol. Drug Des. 73 (2009), 53–61.
26. [26] Babapoor, S., Neef, T., Mittelholzer, C., Girshick, T., Garmendia, A., Shang, H., Khan, M.I., Burkhard, P., A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection. Influenza Res. Treat., 2011, 2012.
27. [27] Wahome, N., Pfeiffer, T., Ambiel, I., Yang, Y., Keppler, O.T., Bosch, V., Burkhard, P., Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem. Biol. Drug Des. 80 (2012), 349–357.
28. [28] King, N.P., Bale, J.B., Sheffler, W., McNamara, D.E., Gonen, S., Gonen, T., Yeates, T.O., Baker, D., Accurate design of co-assembling multi-component protein nanomaterials. Nature 510 (2014), 103–108.
29. [29] MaHam, A., Tang, Z., Wu, H., Wang, J., Lin, Y., Protein-based nanomedicine platforms for drug delivery. Small 5 (2009), 1706–1721.
30. [30] Lee, L.A., Wang, Q., Adaptations of nanoscale viruses and other protein cages for medical applications. Nanomed.: Nanotechnol., Biol. Med. 2 (2006), 137–149.
31. [31] Munro, H.N., Linder, M.C., Ferritin: structure, biosynthesis, and role in iron metabolism. Physiol. Rev. 58 (1978), 317–396.
32. [32] d'Estaintot, B.L., Santambrogio, P., Granier, T., Gallois, B., Chevalier, J.M., Precigoux, G., Levi, S., Arosio, P., Crystal structure and biochemical properties of the human mitochondrial ferritin and its mutant Ser144Ala. J. Mol. Biol. 340 (2004), 277–293.
33. [33] Kramer, R.M., Li, C., Carter, D.C., Stone, M.O., Naik, R.R., Engineered protein cages for nanomaterial synthesis. J. Am. Chem. Soc. 126 (2004), 13282–13286.
34. [34] Hosein, H.-A., Strongin, D.R., Allen, M., Douglas, T., Iron and cobalt oxide and metallic nanoparticles prepared from ferritin. Langmuir 20 (2004), 10283–10287.
35. [35] Sánchez, P., Valero, E., Gálvez, N., Domínguez-Vera, J.M., Marinone, M., Poletti, G., Corti, M., Lascialfari, A., MRI relaxation properties of water-soluble apoferritin-encapsulated gadolinium oxide-hydroxide nanoparticles. Dalton Trans., 2009, 800–804.
36. [36] Stefanini, S., Cavallo, S., Wang, C.-Q., Tataseo, P., Vecchini, P., Giartosio, A., Chiancone, E., Thermal stability of horse spleen apoferritin and human recombinant H apoferritin. Arch. Biochem. Biophys. 325 (1996), 58–64.
37. [37] Bryce, C.F., Crichton, R.R., The catalytic activity of horse spleen apoferritin. Preliminary kinetic studies and the effect of chemical modification. Biochem. J. 133 (1973), 301–309.
38. [38] Kim, M., Rho, Y., Jin, K.S., Ahn, B., Jung, S., Kim, H., Ree, M., pH-dependent structures of ferritin and apoferritin in solution: disassembly and reassembly. Biomacromolecules 12 (2011), 1629–1640.
39. [39] Aime, S., Frullano, L., Geninatti Crich, S., Compartmentalization of a gadolinium complex in the apoferritin cavity: a route to obtain high relaxivity contrast agents for magnetic resonance imaging. Angew. Chem. Int. Ed. 41 (2002), 1017–1019.
40. [40] Yan, F., Zhang, Y., Yuan, H.-k., Gregas, M.K., Vo-Dinh, T., Apoferritin protein cages: a novel drug nanocarrier for photodynamic therapy. Chem. Commun., 4579-4581, 2008.
41. [41] Yang, Z., Wang, X., Diao, H., Zhang, J., Li, H., Sun, H., Guo, Z., Encapsulation of platinum anticancer drugs by apoferritin. Chem. Commun., 3453-3455, 2007.
42. [42] Liu, X., Wei, W., Huang, S., Lin, S.-S., Zhang, X., Zhang, C., Du, Y., Ma, G., Li, M., Mann, S., Ma, D., Bio-inspired protein–gold nanoconstruct with core–void–shell structure: beyond a chemo drug carrier. J. Mater. Chem. B 1 (2013), 3136–3143.
43. [43] Ma-Ham, A., Wu, H., Wang, J., Kang, X., Zhang, Y., Lin, Y., Apoferritin-based nanomedicine platform for drug delivery: equilibrium binding study of daunomycin with DNA. J. Mater. Chem., 21, 2011, 8700.
44. [44] Luo, Y., Wang, X., Du, D., Lin, Y., Hyaluronic acid-conjugated apoferritin nanocages for lung cancer targeted drug delivery. Biomater. Sci. 3 (2015), 1386–1394.
45. [45] Zhen, Z., Tang, W., Chen, H., Lin, X., Todd, T., Wang, G., Cowger, T., Chen, X., Xie, J., RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 7 (2013), 4830–4837.
46. [46] Blazkova, I., Nguyen, H.V., Dostalova, S., Kopel, P., Stanisavljevic, M., Vaculovicova, M., Stiborova, M., Eckschlager, T., Kizek, R., Adam, V., Apoferritin modified magnetic particles as doxorubicin carriers for anticancer drug delivery. Int. J. Mol. Sci. 14 (2013), 13391–13402.
47. [47] Liang, M., Fan, K., Zhou, M., Duan, D., Zheng, J., Yang, D., Feng, J., Yan, X., H-ferritin–nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection. Proc. Natl. Acad. Sci. 111 (2014), 14900–14905.
48. [48] Bellini, M., Mazzucchelli, S., Galbiati, E., Sommaruga, S., Fiandra, L., Truffi, M., Rizzuto, M.A., Colombo, M., Tortora, P., Corsi, F., Prosperi, D., Protein nanocages for self-triggered nuclear delivery of DNA-targeted chemotherapeutics in cancer cells. J. Control. Release 196 (2014), 184–196.
49. [49] Lin, X., Xie, J., Niu, G., Zhang, F., Gao, H., Yang, M., Quan, Q., Aronova, M.A., Zhang, G., Lee, S., Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett. 11 (2011), 814–819.
50. [50] Lin, X., Xie, J., Zhu, L., Lee, S., Niu, G., Ma, Y., Kim, K., Chen, X., Hybrid ferritin nanoparticles as activatable probes for tumor imaging. Angew. Chem. 123 (2011), 1607–1610.
51. [51] Marchesi, V., Tillack, T., Jackson, R., Segrest, J., Scott, R., Chemical characterization and surface orientation of the major glycoprotein of the human erythrocyte membrane. Proc. Natl. Acad. Sci. 69 (1972), 1445–1449.
52. [52] Uchida, M., Flenniken, M.L., Allen, M., Willits, D.A., Crowley, B.E., Brumfield, S., Willis, A.F., Jackiw, L., Jutila, M., Young, M.J., Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J. Am. Chem. Soc. 128 (2006), 16626–16633.
53. [53] Jeon, J.O., Kim, S., Choi, E., Shin, K., Cha, K., So, I.-S., Kim, S.-J., Jun, E., Kim, D., Ahn, H.J., Designed nanocage displaying ligand-specific peptide bunches for high affinity and biological activity. ACS Nano 7 (2013), 7462–7471.
54. [54] Lee, W., Seo, J., Kwak, S., Park, E.J., Na, D.H., Kim, S., Lee, Y.M., Kim, I.S., Bae, J.S., A double-chambered protein nanocage loaded with thrombin receptor agonist peptide (TRAP) and γ-carboxyglutamic acid of protein C (PC-gla) for sepsis treatment. Adv. Mater. 27 (2015), 6637–6643.
55. [55] Hainfeld, J.F., Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy. Proc. Natl. Acad. Sci. 89 (1992), 11064–11068.
56. [56] Kang, H.J., Kang, Y.J., Lee, Y.M., Shin, H.H., Chung, S.J., Kang, S., Developing an antibody-binding protein cage as a molecular recognition drug modular nanoplatform. Biomaterials 33 (2012), 5423–5430.
57. [57] Han, J.-A., Kang, Y.J., Shin, C., Ra, J.-S., Shin, H.-H., Hong, S.Y., Do, Y., Kang, S., Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development. Nanomed.: Nanotechnol., Biol. Med. 10 (2014), 561–569.
58. [58] Lee, E.J., Lee, S.J., Kang, Y.S., Ryu, J.H., Kwon, K.C., Jo, E., Yhee, J.Y., Kwon, I.C., Kim, K., Lee, J., Engineered proteinticles for targeted delivery of siRNA to cancer cells. Adv. Funct. Mater. 25 (2015), 1279–1286.
59. [59] Santoro, M.G., Heat shock factors and the control of the stress response. Biochem. Pharmacol. 59 (2000), 55–63.
60. [60] Sun, Y., MacRae, T.H., Small heat shock proteins: molecular structure and chaperone function. Cell. Mol. Life Sci. 62 (2005), 2460–2476.
61. [61] Kim, K.K., Kim, R., Kim, S.-H., Crystal structure of a small heat-shock protein. Nature 394 (1998), 595–599.
62. [62] Bova, M.P., Huang, Q., Ding, L., Horwitz, J., Subunit exchange, conformational stability, and chaperone-like function of the small heat shock protein 16.5 from Methanococcus jannaschii. J. Biol. Chem. 277 (2002), 38468–38475.
63. [63] Flenniken, M.L., Willits, D.A., Brumfield, S., Young, M.J., Douglas, T., The small heat shock protein cage from Methanococcus jannaschii is a versatile nanoscale platform for genetic and chemical modification. Nano Lett. 3 (2003), 1573–1576.
64. [64] Murata, M., Narahara, S., Kawano, T., Hamano, N., Piao, J.S., Kang, J.H., Ohuchida, K., Murakami, T., Hashizume, M., Design and function of engineered protein nanocages as a drug delivery system for targeting pancreatic cancer cells via neuropilin-1. Mol. Pharm. 12 (2015), 1422–1430.
65. [65] Flenniken, M.L., Liepold, L.O., Crowley, B.E., Willits, D.A., Young, M.J., Douglas, T., Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem. Commun., 2005, 447–449.
66. [66] Toita, R., Murata, M., Abe, K., Narahara, S., Piao, J.S., Kang, J.H., Ohuchida, K., Hashizume, M., Biological evaluation of protein nanocapsules containing doxorubicin. Int. J. Nanomedicine 8 (2013), 1989–1999.
67. [67] Toita, R., Murata, M., Abe, K., Narahara, S., Piao, J.S., Kang, J.H., Hashizume, M., A nanocarrier based on a genetically engineered protein cage to deliver doxorubicin to human hepatocellular carcinoma cells. Chem. Commun. (Camb.) 49 (2013), 7442–7444.
68. [68] Liepold, L.O., Abedin, M.J., Buckhouse, E.D., Frank, J.A., Young, M.J., Douglas, T., Supramolecular protein cage composite MR contrast agents with extremely efficient relaxivity properties. Nano Lett. 9 (2009), 4520–4526.
69. [69] Uchida, M., Kosuge, H., Terashima, M., Willits, D.A., Liepold, L.O., Young, M.J., McConnell, M.V., Douglas, T., Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano 5 (2011), 2493–2502.
70. [70] Berger, W., Steiner, E., Grusch, M., Elbling, L., Micksche, M., Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell. Mol. Life Sci. 66 (2009), 43–61.
71. [71] Stephen, A.G., Raval-Fernandes, S., Huynh, T., Torres, M., Kickhoefer, V.A., Rome, L.H., Assembly of vault-like particles in insect cells expressing only the major vault protein. J. Biol. Chem. 276 (2001), 23217–23220.
72. [72] Goldsmith, L.E., Yu, M., Rome, L.H., Monbouquette, H.G., Vault nanocapsule dissociation into halves triggered at low pH. Biochemistry 46 (2007), 2865–2875.
73. [73] Esfandiary, R., Kickhoefer, V.A., Rome, L.H., Joshi, S.B., Middaugh, C.R., Structural stability of vault particles. J. Pharm. Sci. 98 (2009), 1376–1386.
74. [74] Kickhoefer, V.A., Garcia, Y., Mikyas, Y., Johansson, E., Zhou, J.C., Raval-Fernandes, S., Minoofar, P., Zink, J.I., Dunn, B., Stewart, P.L., Engineering of vault nanocapsules with enzymatic and fluorescent properties. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 4348–4352.
75. [75] Kickhoefer, V.A., Han, M., Raval-Fernandes, S., Poderycki, M.J., Moniz, R.J., Vaccari, D., Silvestry, M., Stewart, P.L., Kelly, K.A., Rome, L.H., Targeting vault nanoparticles to specific cell surface receptors. ACS Nano 3 (2008), 27–36.
76. [76] Mikyas, Y., Makabi, M., Raval-Fernandes, S., Harrington, L., Kickhoefer, V.A., Rome, L.H., Stewart, P.L., Cryoelectron microscopy imaging of recombinant and tissue derived vaults: localization of the MVP N termini and VPARP. J. Mol. Biol. 344 (2004), 91–105.
77. [77] Han, M., Kickhoefer, V.A., Nemerow, G.R., Rome, L.H., Targeted vault nanoparticles engineered with an endosomolytic peptide deliver biomolecules to the cytoplasm. ACS Nano 5 (2011), 6128–6137.
78. [78] Lai, C.Y., Wiethoff, C.M., Kickhoefer, V.A., Rome, L.H., Nemerow, G.R., Vault nanoparticles containing an adenovirus-derived membrane lytic protein facilitate toxin and gene transfer. ACS Nano 3 (2009), 691–699.
79. [79] Champion, C.I., Kickhoefer, V.A., Liu, G., Moniz, R.J., Freed, A.S., Bergmann, L.L., Vaccari, D., Raval-Fernandes, S., Chan, A.M., Rome, L.H., Kelly, K.A., A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One, 4, 2009, e5409.
80. [80] Kar, U.K., Jiang, J., Champion, C.I., Salehi, S., Srivastava, M., Sharma, S., Rabizadeh, S., Niazi, K., Kickhoefer, V., Rome, L.H., Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice. PLoS One, 7, 2012, e38553.
81. [81] Kar, U.K., Srivastava, M.K., Andersson, A., Baratelli, F., Huang, M., Kickhoefer, V.A., Dubinett, S.M., Rome, L.H., Sharma, S., Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One, 6, 2011, e18758.
82. [82] Buehler, D.C., Marsden, M.D., Shen, S., Toso, D.B., Wu, X., Loo, J.A., Zhou, Z.H., Kickhoefer, V.A., Wender, P.A., Zack, J.A., Rome, L.H., Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS Nano 8 (2014), 7723–7732.
83. [83] Buehler, D.C., Toso, D.B., Kickhoefer, V.A., Zhou, Z.H., Rome, L.H., Vaults engineered for hydrophobic drug delivery. Small 7 (2011), 1432–1439.
84. [84] Dalmau, M., Lim, S., Chen, H.C., Ruiz, C., Wang, S.W., Thermostability and molecular encapsulation within an engineered caged protein scaffold. Biotechnol. Bioeng. 101 (2008), 654–664.
85. [85] Molino, N.M., Anderson, A.K., Nelson, E.L., Wang, S.-W., Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano 7 (2013), 9743–9752.
86. [86] Ren, D., Kratz, F., Wang, S.W., Protein nanocapsules containing doxorubicin as a pH-responsive delivery system. Small 7 (2011), 1051–1060.
87. [87] Ren, D., Dalmau, M., Randall, A., Shindel, M.M., Baldi, P., Wang, S.W., Biomimetic design of protein nanomaterials for hydrophobic molecular transport. Adv. Funct. Mater. 22 (2012), 3170–3180.
88. [88] Ren, D., Kratz, F., Wang, S.-W., Engineered drug-protein nanoparticle complexes for folate receptor targeting. Biochem. Eng. J. 89 (2014), 33–41.
89. [89] Suci, P.A., Kang, S., Young, M., Douglas, T., A streptavidin–protein cage Janus particle for polarized targeting and modular functionalization. J. Am. Chem. Soc. 131 (2009), 9164–9165.
90. [90] Suci, P., Kang, S., Gmür, R., Douglas, T., Young, M., Targeted delivery of a photosensitizer to Aggregatibacter actinomycetemcomitans biofilm. Antimicrob. Agents Chemother. 54 (2010), 2489–2496.
91. [91] Moon, H., Lee, J., Kim, H., Heo, S., Min, J., Kang, S., Genetically engineering encapsulin protein cage nanoparticle as a SCC-7 cell targeting optical nanoprobe. Biomater. Res., 18, 2014, 1.
92. [92] Moon, H., Lee, J., Min, J., Kang, S., Developing genetically engineered encapsulin protein cage nanoparticles as a targeted delivery nanoplatform. Biomacromolecules 15 (2014), 3794–3801.
93. [93] Seebeck, F.P., Woycechowsky, K.J., Zhuang, W., Rabe, J.P., Hilvert, D., A simple tagging system for protein encapsulation. J. Am. Chem. Soc. 128 (2006), 4516–4517.
94. [94] Worsdorfer, B., Pianowski, Z., Hilvert, D., Efficient in vitro encapsulation of protein cargo by an engineered protein container. J. Am. Chem. Soc. 134 (2012), 909–911.
95. [95] Wörsdörfer, B., Woycechowsky, K.J., Hilvert, D., Directed evolution of a protein container. Science 331 (2011), 589–592.
96. [96] Ra, J.S., Shin, H.H., Kang, S., Do, Y., Lumazine synthase protein cage nanoparticles as antigen delivery nanoplatforms for dendritic cell-based vaccine development. Clin. Exp. Vaccine Res. 3 (2014), 227–234.
97. [97] Min, J., Kim, S., Lee, J., Kang, S., Lumazine synthase protein cage nanoparticles as modular delivery platforms for targeted drug delivery. RSC Adv. 4 (2014), 48596–48600.
98. [98] Douglas, T., Young, M., Viruses: making friends with old foes. Science 312 (2006), 873–875.
99. [99] Ma, Y., Nolte, R.J., Cornelissen, J.J., Virus-based nanocarriers for drug delivery. Adv. Drug Deliv. Rev. 64 (2012), 811–825.
100. [100] Speir, J.A., Munshi, S., Wang, G., Baker, T.S., Johnson, J.E., Structures of the native and swollen forms of cowpea chlorotic mottle virus determined by X-ray crystallography and cryo-electron microscopy. Structure 3 (1995), 63–78.
101. [101] Brumfield, S., Willits, D., Tang, L., Johnson, J.E., Douglas, T., Young, M., Heterologous expression of the modified coat protein of cowpea chlorotic mottle bromovirus results in the assembly of protein cages with altered architectures and function. J. Gen. Virol. 85 (2004), 1049–1053.
102. [102] Tang, J., Johnson, J.M., Dryden, K.A., Young, M.J., Zlotnick, A., Johnson, J.E., The role of subunit hinges and molecular “switches” in the control of viral capsid polymorphism. J. Struct. Biol. 154 (2006), 59–67.
103. [103] Minten, I.J., Hendriks, L.J., Nolte, R.J., Cornelissen, J.J., Controlled encapsulation of multiple proteins in virus capsids. J. Am. Chem. Soc. 131 (2009), 17771–17773.
104. [104] Gillitzer, E., Suci, P., Young, M., Douglas, T., Controlled ligand display on a symmetrical protein-cage architecture through mixed assembly. Small 2 (2006), 962–966.
105. [105] Gillitzer, E., Willits, D., Young, M., Douglas, T., Chemical modification of a viral cage for multivalent presentation. Chem. Commun., 2002, 2390–2391.
106. [106] Suci, P.A., Varpness, Z., Gillitzer, E., Douglas, T., Young, M., Targeting and photodynamic killing of a microbial pathogen using protein cage architectures functionalized with a photosensitizer. Langmuir 23 (2007), 12280–12286.
107. [107] Brasch, M., de la Escosura, A., Ma, Y., Uetrecht, C., Heck, A.J., Torres, T., Cornelissen, J.J., Encapsulation of phthalocyanine supramolecular stacks into virus-like particles. J. Am. Chem. Soc. 133 (2011), 6878–6881.
108. [108] Porta, C., Spall, V.E., Findlay, K.C., Gergerich, R.C., Farrance, C.E., Lomonossoff, G.P., Cowpea mosaic virus-based chimaeras: effects of inserted peptides on the phenotype, host range, and transmissibility of the modified viruses. Virology 310 (2003), 50–63.
109. [109] Ochoa, W.F., Chatterji, A., Lin, T., Johnson, J.E., Generation and structural analysis of reactive empty particles derived from an icosahedral virus. Chem. Biol. 13 (2006), 771–778.
110. [110] Singh, P., Gonzalez, M.J., Manchester, M., Viruses and their uses in nanotechnology. Drug Dev. Res. 67 (2006), 23–41.
111. [111] Aljabali, A.A., Shukla, S., Lomonossoff, G.P., Steinmetz, N.F., Evans, D.J., CPMV-DOX delivers. Mol. Pharm. 10 (2012), 3–10.
112. [112] Yildiz, I., Lee, K.L., Chen, K., Shukla, S., Steinmetz, N.F., Infusion of imaging and therapeutic molecules into the plant virus-based carrier cowpea mosaic virus: cargo-loading and delivery. J. Control. Release 172 (2013), 568–578.
113. [113] Steinmetz, N.F., Hong, V., Spoerke, E.D., Lu, P., Breitenkamp, K., Finn, M., Manchester, M., Buckyballs meet viral nanoparticles: candidates for biomedicine. J. Am. Chem. Soc. 131 (2009), 17093–17095.
114. [114] Wang, Q., Kaltgrad, E., Lin, T., Johnson, J.E., Finn, M., Natural supramolecular building blocks: wild-type cowpea mosaic virus. Chem. Biol. 9 (2002), 805–811.
115. [115] Wang, Q., Lin, T., Tang, L., Johnson, J.E., Finn, M., Icosahedral virus particles as addressable nanoscale building blocks. Angew. Chem. Int. Ed. 41 (2002), 459–462.
116. [116] Wen, A.M., Shukla, S., Saxena, P., Aljabali, A.A., Yildiz, I., Dey, S., Mealy, J.E., Yang, A.C., Evans, D.J., Lomonossoff, G.P., Interior engineering of a viral nanoparticle and its tumor homing properties. Biomacromolecules 13 (2012), 3990–4001.
117. [117] Wang, Q., Lin, T., Johnson, J.E., Finn, M., Natural supramolecular building blocks: cysteine-added mutants of cowpea mosaic virus. Chem. Biol. 9 (2002), 813–819.
118. [118] Chatterji, A., Burns, L., Taylor, S., Lomonossoff, G., Johnson, J., Lin, T., Porta, C., Cowpea mosaic virus: from the presentation of antigenic peptides to the display of active biomaterials. Intervirology 45 (2002), 362–370.
119. [119] Steinmetz, N.F., Lomonossoff, G.P., Evans, D.J., Cowpea mosaic virus for material fabrication: addressable carboxylate groups on a programmable nanoscaffold. Langmuir 22 (2006), 3488–3490.
120. [120] Strable, E., Johnson, J.E., Finn, M., Natural nanochemical building blocks: icosahedral virus particles organized by attached oligonucleotides. Nano Lett. 4 (2004), 1385–1389.
121. [121] Raja, K.S., Wang, Q., Finn, M., Icosahedral virus particles as polyvalent carbohydrate display platforms. Chembiochem 4 (2003), 1348–1351.
122. [122] Gupta, S.S., Kuzelka, J., Singh, P., Lewis, W.G., Manchester, M., Finn, M., Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug. Chem. 16 (2005), 1572–1579.
123. [123] Kaltgrad, E., O'Reilly, M.K., Liao, L., Han, S., Paulson, J.C., Finn, M., On-virus construction of polyvalent glycan ligands for cell-surface receptors. J. Am. Chem. Soc. 130 (2008), 4578–4579.
124. [124] Astronomo, R.D., Kaltgrad, E., Udit, A.K., Wang, S.-K., Doores, K.J., Huang, C.-Y., Pantophlet, R., Paulson, J.C., Wong, C.-H., Finn, M., Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem. Biol. 17 (2010), 357–370.
125. [125] Gupta, S.S., Raja, K.S., Kaltgrad, E., Strable, E., Finn, M., Virus–glycopolymer conjugates by copper (I) catalysis of atom transfer radical polymerization and azide–alkyne cycloaddition. Chem. Commun., 2005, 4315–4317.
126. [126] Brunel, F.M., Lewis, J.D., Destito, G., Steinmetz, N.F., Manchester, M., Stuhlmann, H., Dawson, P.E., Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Nano Lett. 10 (2010), 1093–1097.
127. [127] Steinmetz, N.F., Ablack, A.L., Hickey, J.L., Ablack, J., Manocha, B., Mymryk, J.S., Luyt, L.G., Lewis, J.D., Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing peptide receptors. Small 7 (2011), 1664–1672.
128. [128] Wu, Z., Chen, K., Yildiz, I., Dirksen, A., Fischer, R., Dawson, P.E., Steinmetz, N.F., Development of viral nanoparticles for efficient intracellular delivery. Nanoscale 4 (2012), 3567–3576.
129. [129] Hovlid, M.L., Steinmetz, N.F., Laufer, B., Lau, J.L., Kuzelka, J., Wang, Q., Hyypiä, T., Nemerow, G.R., Kessler, H., Manchester, M., Guiding plant virus particles to integrin-displaying cells. Nanoscale 4 (2012), 3698–3705.
130. [130] Chatterji, A., Ochoa, W., Shamieh, L., Salakian, S.P., Wong, S.M., Clinton, G., Ghosh, P., Lin, T., Johnson, J.E., Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug. Chem. 15 (2004), 807–813.
131. [131] Cargile, B.J., McLuckey, S.A., Stephenson, J.L., Identification of bacteriophage MS2 coat protein from E. coli lysates via ion trap collisional activation of intact protein ions. Anal. Chem. 73 (2001), 1277–1285.
132. [132] Johnson, H.R., Hooker, J.M., Francis, M.B., Clark, D.S., Solubilization and stabilization of bacteriophage MS2 in organic solvents. Biotechnol. Bioeng. 97 (2007), 224–234.
133. [133] Valegård, K., Liljas, L., Fridborg, K., Unge, T., The three-dimensional structure of the bacterial virus MS2. Nature 345 (1990), 36–41.
134. [134] Brown, S.D., Fiedler, J.D., Finn, M., Assembly of hybrid bacteriophage Qβ virus-like particles. Biochemistry 48 (2009), 11155–11157.
135. [135] Galaway, F.A., Stockley, P.G., MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform. Mol. Pharm. 10 (2013), 59–68.
136. [136] Pan, Y., Zhang, Y., Jia, T., Zhang, K., Li, J., Wang, L., Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J. 279 (2012), 1198–1208.
137. [137] Pan, Y., Jia, T., Zhang, Y., Zhang, K., Zhang, R., Li, J., Wang, L., MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Int. J. Nanomedicine 7 (2012), 5957–5967.
138. [138] Wu, M., Sherwin, T., Brown, W.L., Stockley, P.G., Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine 1 (2005), 67–76.
139. [139] Ashley, C.E., Carnes, E.C., Phillips, G.K., Durfee, P.N., Buley, M.D., Lino, C.A., Padilla, D.P., Phillips, B., Carter, M.B., Willman, C.L., Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano 5 (2011), 5729–5745.
140. [140] Stephanopoulos, N., Tong, G.J., Hsiao, S.C., Francis, M.B., Dual-surface modified virus capsids for targeted delivery of photodynamic agents to cancer cells. ACS Nano 4 (2010), 6014–6020.
141. [141] Ashcroft, A.E., Lago, H., Macedo, J., Horn, W.T., Stonehouse, N.J., Stockley, P.G., Engineering thermal stability in RNA phage capsids via disulphide bonds. J. Nanosci. Nanotechnol. 5 (2005), 2034–2041.
142. [142] Valegård, K., Fridborg, K., Liljas, L., Crystallization and preliminary x-ray diffraction studies of the bacteriophage Qβ. Acta Crystallogr. D Biol. Crystallogr. 50 (1994), 105–109.
143. [143] Kozlovska, T.M., Cielens, I., Vasiljeva, I., Strelnikova, A., Kazaks, A., Dislers, A., Dreilina, D., Ose, V., Gusars, I., Pumpens, P., RNA phage Qβ coat protein as a carrier for foreign epitopes. Intervirology 39 (1996), 9–15.
144. [144] Vasiljeva, I., Kozlovska, T., Cielens, I., Strelnikova, A., Kazaks, A., Ose, V., Pumpens, P., Mosaic Qβ coats as a new presentation model. FEBS Lett. 431 (1998), 7–11.
145. [145] Prasuhn, D.E., Singh, P., Strable, E., Brown, S., Manchester, M., Finn, M., Plasma clearance of bacteriophage Qβ particles as a function of surface charge. J. Am. Chem. Soc. 130 (2008), 1328–1334.
146. [146] Pokorski, J.K., Hovlid, M.L., Finn, M.G., Cell targeting with hybrid qbeta virus-like particles displaying epidermal growth factor. Chembiochem 12 (2011), 2441–2447.
147. [147] Rhee, J.K., Baksh, M., Nycholat, C., Paulson, J.C., Kitagishi, H., Finn, M.G., Glycan-targeted virus-like nanoparticles for photodynamic therapy. Biomacromolecules 13 (2012), 2333–2338.
148. [148] Storni, T., Ruedl, C., Schwarz, K., Schwendener, R.A., Renner, W.A., Bachmann, M.F., Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 172 (2004), 1777–1785.
149. [149] Goldinger, S.M., Dummer, R., Baumgaertner, P., Mihic-Probst, D., Schwarz, K., Hammann-Haenni, A., Willers, J., Geldhof, C., Prior, J.O., Kundig, T.M., Michielin, O., Bachmann, M.F., Speiser, D.E., Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur. J. Immunol. 42 (2012), 3049–3061.
150. [150] Zeng, Q.B., Wen, H.B., Wen, Q., Chen, X.H., Wang, Y.G., Xuan, W.L., Liang, J.S., Wan, S.H., Cucumber mosaic virus as drug delivery vehicle for doxorubicin. Biomaterials 34 (2013), 4632–4642.
151. [151] Zochowska, M., Paca, A., Schoehn, G., Andrieu, J.P., Chroboczek, J., Dublet, B., Szolajska, E., Adenovirus dodecahedron, as a drug delivery vector. Plos One, 4, 2009.
152. [152] Shan, L.L., Cui, S.S., Du, C.L., Wan, S.A., Qian, Z.Y., Achilefu, S., Gu, Y.Q., A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 33 (2012), 146–162.
153. [153] Kwon, K.C., Ryu, J.H., Lee, J.H., Lee, E.J., Kwon, I.C., Kim, K., Lee, J., Proteinticle/gold core/shell nanoparticles for targeted cancer therapy without nanotoxicity. Adv. Mater. 26 (2014), 6436–6441.
154. [154] Choi, K.M., Kim, K., Kwon, I.C., Kim, I.-S., Ahn, H.J., Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity in vivo. Mol. Pharm. 10 (2012), 18–25.
155. [155] Juarez, V., Pasolli, H.A., Hellwig, A., Garbi, N., Arregui, A.C., Virus-like particles harboring CCL19, IL-2 and HPV16 E7 elicit protective T cell responses in HLA-A2 transgenic mice. Open Virol. J. 6 (2012), 270–276.
156. [156] Lockney, D.M., Guenther, R.N., Loo, L., Overton, W., Antonelli, R., Clark, J., Hu, M., Luft, C., Lommel, S.A., Franzen, S., The red clover necrotic mosaic virus capsid as a multifunctional cell targeting plant viral nanoparticle. Bioconjug. Chem. 22 (2011), 67–73.
157. [157] Kaczmarczyk, S.J., Sitaraman, K., Young, H.A., Hughes, S.H., Chatterjee, D.K., Protein delivery using engineered virus-like particles. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 16998–17003.
158. [158] Ren, Y., Wong, S.M., Lim, L.Y., Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin. Bioconjug. Chem. 18 (2007), 836–843.
159. [159] Franco, D., Liu, W.M., Gardiner, D.F., Hahn, B.H., Ho, D.D., CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells. J. Acquir. Immune Defic. Syndr. 56 (2011), 393–400.
160. [160] Chou, M.I., Hsieh, Y.F., Wang, M., Chang, J.T., Chang, D., Zouali, M., Tsay, G.J., In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles. J. Biomed. Sci., 17, 2010, 51.
161. [161] Niikura, K., Sugimura, N., Musashi, Y., Mikuni, S., Matsuo, Y., Kobayashi, S., Nagakawa, K., Takahara, S., Takeuchi, C., Sawa, H., Kinjo, M., Ijiro, K., Virus-like particles with removable cyclodextrins enable glutathione-triggered drug release in cells. Mol. BioSyst. 9 (2013), 501–507.
162. [162] Zhang, R.X., Zhang, S., Li, M., Chen, C.Y., Yao, Q.Z., Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine 28 (2010), 5114–5127.
163. [163] Abbing, A., Blaschke, U.K., Grein, S., Kretschmar, M., Stark, C.M., Thies, M.J., Walter, J., Weigand, M., Woith, D.C., Hess, J., Reiser, C.O., Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J. Biol. Chem. 279 (2004), 27410–27421.
164. [164] Zhao, Q.H., Chen, W.H., Chen, Y.D., Zhang, L.M., Zhang, J.P., Zhang, Z.J., Self-assembled virus-like particles from rotavirus structural protein VP6 for targeted drug delivery. Bioconjug. Chem. 22 (2011), 346–352.
165. [165] Patterson, D.P., Rynda-Apple, A., Harmsen, A.L., Harmsen, A.G., Douglas, T., Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza. ACS Nano 7 (2013), 3036–3044.
166. [166] Dickerson, M.B., Sandhage, K.H., Naik, R.R., Protein- and peptide-directed syntheses of inorganic materials. Chem. Rev. 108 (2008), 4935–4978.
167. [167] Woolfson, D.N., Mahmoud, Z.N., More than just bare scaffolds: towards multi-component and decorated fibrous biomaterials. Chem. Soc. Rev. 39 (2010), 3464–3479.
168. [168] Ulijn, R.V., Woolfson, D.N., Peptide and protein based materials in 2010: from design and structure to function and application. Chem. Soc. Rev. 39 (2010), 3349–3350.
169. [169] Zhang, S.G., Fabrication of novel biomaterials through molecular self-assembly. Nat. Biotechnol. 21 (2003), 1171–1178.
170. [170] Banwell, E.F., Abelardo, E.S., Adams, D.J., Birchall, M.A., Corrigan, A., Donald, A.M., Kirkland, M., Serpell, L.C., Butler, M.F., Woolfson, D.N., Rational design and application of responsive alpha-helical peptide hydrogels. Nat. Mater. 8 (2009), 596–600.
171. [171] Burkhard, P., Stetefeld, J., Strelkov, S.V., Coiled coils: a highly versatile protein folding motif. Trends Cell Biol. 11 (2001), 82–88.
172. [172] Papapostolou, D., Smith, A.M., Atkins, E.D.T., Oliver, S.J., Ryadnov, M.G., Serpell, L.C., Woolfson, D.N., Engineering nanoscale order into a designed protein fiber. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 10853–10858.
173. [173] Pandya, M.J., Spooner, G.M., Sunde, M., Thorpe, J.R., Rodger, A., Woolfson, D.N., Sticky-end assembly of a designed peptide fiber provides insight into protein fibrillogenesis. Biochem.-Us 39 (2000), 8728–8734.
174. [174] Ghosh, A., Haverick, M., Stump, K., Yang, X.Y., Tweedle, M.F., Goldberger, J.E., Fine-tuning the pH trigger of self-assembly. J. Am. Chem. Soc. 134 (2012), 3647–3650.
175. [175] Luo, J.N., Tong, Y.W., Self-assembly of collagen-mimetic peptide amphiphiles into biofunctional nanofiber. ACS Nano 5 (2011), 7739–7747.
176. [176] Boato, F., Thomas, R.M., Ghasparian, A., Freund-Renard, A., Moehle, K., Robinson, J.A., Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. Angew. Chem. Int. Ed. 46 (2007), 9015–9018.
177. [177] Raman, S., Machaidze, G., Lustig, A., Aebi, U., Burkhard, P., Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine 2 (2006), 95–102.
178. [178] Yang, Y.K., Ringler, P., Muller, S.A., Burkhard, P., Optimizing the refolding conditions of self-assembling polypeptide nanoparticles that serve as repetitive antigen display systems. J. Struct. Biol. 177 (2012), 168–176.
179. [179] Kaba, S.A., McCoy, M.E., Doll, T.A.P.F., Brando, C., Guo, Q., Dasgupta, D., Yang, Y.K., Mittelholzer, C., Spaccapelo, R., Crisanti, A., Burkhard, P., Lanar, D.E., Protective antibody and CD8(+) T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. Plos One, 7, 2012.
180. [180] Yang, Y.K., Neef, T., Mittelholzer, C., Garayoa, E.G., Blauenstein, P., Schibli, R., Aebi, U., Burkhard, P., The biodistribution of self-assembling protein nanoparticles shows they are promising vaccine platforms. J. Nanobiotechnol., 11, 2013.
181. [181] Gerstmayr, M., Ilk, N., Schabussova, I., Jahn-Schmid, B., Egelseer, E.M., Sleytr, U.B., Ebner, C., Bohle, B., A novel approach to specific allergy treatment: the recombinant allergen-S-layer fusion protein rSbsC-bet v 1 matures dendritic cells that prime Th0/Th1 and IL-10-producing regulatory T cells. J. Immunol. 179 (2007), 7270–7275.
182. [182] King, N.P., Sheffler, W., Sawaya, M.R., Vollmar, B.S., Sumida, J.P., André, I., Gonen, T., Yeates, T.O., Baker, D., Computational design of self-assembling protein nanomaterials with atomic level accuracy. Science 336 (2012), 1171–1174.
183. [183] Bale, J.B., Park, R.U., Liu, Y.X., Gonen, S., Gonen, T., Cascio, D., King, N.P., Yeates, T.O., Baker, D., Structure of a designed tetrahedral protein assembly variant engineered to have improved soluble expression. Protein Sci. 24 (2015), 1695–1701.
184. [184] Lai, Y.-T., Cascio, D., Yeates, T.O., Structure of a 16-nm cage designed by using protein oligomers. Science, 336, 2012, 1129.
185. [185] Padilla, J.E., Colovos, C., Yeates, T.O., Nanohedra: using symmetry to design self-assembling protein cages, layers, crystals, and filaments. Proc. Natl. Acad. Sci. 98 (2001), 2217–2221.
186. [186] Lai, Y.T., Reading, E., Hura, G.L., Tsai, K.L., Laganowsky, A., Asturias, F.J., Tainer, J.A., Robinson, C.V., Yeates, T.O., Structure of a designed protein cage that self-assembles into a highly porous cube. Nat. Chem. 6 (2014), 1065–1071.
187. [187] Takahashi, T., Kuyucak, S., Functional properties of threefold and fourfold channels in ferritin deduced from electrostatic calculations. Biophys. J. 84 (2003), 2256–2263.
188. [188] Pan, Y.-H., Sader, K., Powell, J.J., Bleloch, A., Gass, M., Trinick, J., Warley, A., Li, A., Brydson, R., Brown, A., 3D morphology of the human hepatic ferritin mineral core: new evidence for a subunit structure revealed by single particle analysis of HAADF-STEM images. J. Struct. Biol. 166 (2009), 22–31.
189. [189] Yang, D., Nagayama, K., Permeation of small molecules into the cavity of ferritin as revealed by proton nuclear magnetic resonance relaxation. Biochem. J. 307 (1995), 253–256.
190. [190] Rhee, J.-K., Hovlid, M., Fiedler, J.D., Brown, S.D., Manzenrieder, F., Kitagishi, H., Nycholat, C., Paulson, J.C., Finn, M., Colorful virus-like particles: fluorescent protein packaging by the Qβ capsid. Biomacromolecules 12 (2011), 3977–3981.
191. [191] Fiedler, J.D., Brown, S.D., Lau, J.L., Finn, M., RNA-directed packaging of enzymes within virus-like particles. Angew. Chem. Int. Ed. 49 (2010), 9648–9651.
192. [192] Kwak, M., Minten, I.J., Anaya, D.-M., Musser, A.J., Brasch, M., Nolte, R.J., Müllen, K., Cornelissen, J.J., Herrmann, A., Virus-like particles templated by DNA micelles: a general method for loading virus nanocarriers. J. Am. Chem. Soc. 132 (2010), 7834–7835.
193. [193] Choi, K.-m., Choi, S.-H., Jeon, H., Kim, I.-S., Ahn, H.J., Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA. ACS Nano 5 (2011), 8690–8699.
194. [194] O'Neil, A., Reichhardt, C., Johnson, B., Prevelige, P.E., Douglas, T., Genetically programmed in vivo packaging of protein cargo and its controlled release from bacteriophage P22. Angew. Chem. Int. Ed. 50 (2011), 7425–7428.
195. [195] O'Neil, A., Prevelige, P.E., Basu, G., Douglas, T., Coconfinement of fluorescent proteins: spatially enforced communication of GFP and mCherry encapsulated within the P22 capsid. Biomacromolecules 13 (2012), 3902–3907.
196. [196] Qazi, S., Miettinen, H.M., Wilkinson, R.A., McCoy, K., Douglas, T., Wiedenheft, B., Programmed Self-Assembly of an Active P22-Cas9 Nanocarrier System. Mol Pharm 13 (2016), 1191–1196.
197. [197] Patterson, D.P., Prevelige, P.E., Douglas, T., Nanoreactors by programmed enzyme encapsulation inside the capsid of the bacteriophage P22. ACS Nano 6 (2012), 5000–5009.
198. [198] Patterson, D.P., Schwarz, B., El-Boubbou, K., van der Oost, J., Prevelige, P.E., Douglas, T., Virus-like particle nanoreactors: programmed encapsulation of the thermostable CelB glycosidase inside the P22 capsid. Soft Matter 8 (2012), 10158–10166.
199. [199] Patterson, D.P., Schwarz, B., Waters, R.S., Gedeon, T., Douglas, T., Encapsulation of an enzyme cascade within the bacteriophage P22 virus-like particle. ACS Chem. Biol. 9 (2013), 359–365.
200. [200] Douglas, T., Young, M., Host–guest encapsulation of materials by assembled virus protein cages. Nature 393 (1998), 152–155.
201. [201] Wu, Y., Yang, H., Shin, H.-J., Viruses as self-assembled nanocontainers for encapsulation of functional cargoes. Korean J. Chem. Eng. 30 (2013), 1359–1367.
202. [202] Patel, K.G., Swartz, J.R., Surface functionalization of virus-like particles by direct conjugation using azide–alkyne click chemistry. Bioconjug. Chem. 22 (2011), 376–387.
203. [203] Pokorski, J.K., Steinmetz, N.F., The art of engineering viral nanoparticles. Mol. Pharm. 8 (2010), 29–43.
204. [204] Strable, E., Prasuhn, D.E. Jr., Udit, A.K., Brown, S., Link, A.J., Ngo, J.T., Lander, G., Quispe, J., Potter, C.S., Carragher, B., Unnatural amino acid incorporation into virus-like particles. Bioconjug. Chem. 19 (2008), 866–875.
205. [205] Kovacs, E.W., Hooker, J.M., Romanini, D.W., Holder, P.G., Berry, K.E., Francis, M.B., Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. Bioconjug. Chem. 18 (2007), 1140–1147.
206. [206] Kang, S., Uchida, M., O'Neil, A., Li, R., Prevelige, P.E., Douglas, T., Implementation of p22 viral capsids as nanoplatforms. Biomacromolecules 11 (2010), 2804–2809.
207. [207] Qu, X., Komatsu, T., Sato, T., Glatter, O., Horinouchi, H., Kobayashi, K., Tsuchida, E., Structure, photophysical property, and cytotoxicity of human serum albumin complexed with tris (dicarboxymethylene)[60] fullerene. Bioconjug. Chem. 19 (2008), 1556–1560.
208. [208] Zhao, B., He, Y.-Y., Bilski, P.J., Chignell, C.F., Pristine (C60) and hydroxylated [C60 (OH) 24] fullerene phototoxicity towards HaCaT keratinocytes: type I vs type II mechanisms. Chem. Res. Toxicol. 21 (2008), 1056–1063.
209. [209] Qazi, S., Liepold, L.O., Abedin, M.J., Johnson, B., Prevelige, P., Frank, J.A., Douglas, T., P22 viral capsids as nanocomposite high-relaxivity MRI contrast agents. Mol. Pharm. 10 (2012), 11–17.
210. [210] JoynaláAbedin, M., A click chemistry based coordination polymer inside small heat shock protein. Chem. Commun. 46 (2010), 264–266.
211. [211] Schwarz, B., Douglas, T., Development of virus-like particles for diagnostic and prophylactic biomedical applications. Wires Nanomed Nanobi 7 (2015), 722–735.
212. [212] Lucon, J., Qazi, S., Uchida, M., Bedwell, G.J., LaFrance, B., Prevelige, P.E. Jr., Douglas, T., Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading. Nat. Chem. 4 (2012), 781–788.
213. [213] Pokorski, J.K., Breitenkamp, K., Liepold, L.O., Qazi, S., Finn, M., Functional virus-based polymer–protein nanoparticles by atom transfer radical polymerization. J. Am. Chem. Soc. 133 (2011), 9242–9245.
214. [214] Brayden, D.J., Controlled release technologies for drug delivery. Drug Discov. Today 8 (2003), 976–978.
215. [215] Lo, A., Lin, C.-T., Wu, H.-C., Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol. Cancer Ther. 7 (2008), 579–589.
216. [216] Toita, R., Murata, M., Tabata, S., Abe, K., Narahara, S., Piao, J.S., Kang, J.-H., Hashizume, M., Development of human hepatocellular carcinoma cell-targeted protein cages. Bioconjug. Chem. 23 (2012), 1494–1501.
217. [217] Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., Carotenuto, A., De Feo, G., Caponigro, F., Salomon, D.S., Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366 (2006), 2–16.
218. [218] Li, X., Qiu, L., Zhu, P., Tao, X., Imanaka, T., Zhao, J., Huang, Y., Tu, Y., Cao, X., Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting. Small 8 (2012), 2505–2514.
219. [219] Murata, M., Narahara, S., Umezaki, K., Toita, R., Tabata, S., Piao, J.S., Abe, K., Kang, J.-H., Ohuchida, K., Cui, L., Liver cell specific targeting by the preS1 domain of hepatitis B virus surface antigen displayed on protein nanocages. Int. J. Nanomedicine, 7, 2012, 4353.
220. [220] Destito, G., Schneemann, A., Manchester, M., Biomedical Nanotechnology Using Virus-Based Nanoparticles. 2009, Springer, Viruses and Nanotechnology, 95–122.
221. [221] Rijnboutt, S., Jansen, G., Posthuma, G., Hynes, J.B., Schornagel, J.H., Strous, G.J., Endocytosis of GPI-linked membrane folate receptor-alpha. J. Cell Biol. 132 (1996), 35–47.
222. [222] Lu, Y., Low, P.S., Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 64 (2012), 342–352.
223. [223] Destito, G., Yeh, R., Rae, C.S., Finn, M., Manchester, M., Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem. Biol. 14 (2007), 1152–1162.
224. [224] Daniels, T.R., Delgado, T., Helguera, G., Penichet, M.L., The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121 (2006), 159–176.
225. [225] Daniels, T.R., Delgado, T., Rodriguez, J.A., Helguera, G., Penichet, M.L., The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121 (2006), 144–158.
226. [226] Banerjee, D., Liu, A.P., Voss, N.R., Schmid, S.L., Finn, M., Multivalent display and receptor-mediated endocytosis of transferrin on virus-like particles. Chembiochem 11 (2010), 1273–1279.
227. [227] Ellington, A.D., Szostak, J.W., In vitro selection of RNA molecules that bind specific ligands. Nature 346 (1990), 818–822.
228. [228] Tuerk, C., Gold, L., Systematic evolution of ligands by exponential enrichment—RNA ligands to bacteriophage-T4 DNA-polymerase. Science 249 (1990), 505–510.
229. [229] Tong, G.J., Hsiao, S.C., Carrico, Z.M., Francis, M.B., Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J. Am. Chem. Soc. 131 (2009), 11174–11178.
230. [230] Heitz, F., Morris, M.C., Divita, G., Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 157 (2009), 195–206.
231. [231] Wei, B., Wei, Y., Zhang, K., Wang, J., Xu, R., Zhan, S., Lin, G., Wang, W., Liu, M., Wang, L., Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell penetrating peptide. Biomed. Pharmacother. 63 (2009), 313–318.
232. [232] Carrico, Z.M., Romanini, D.W., Mehl, R.A., Francis, M.B., Oxidative coupling of peptides to a virus capsid containing unnatural amino acids. Chem. Commun., 2008, 1205–1207.
233. [233] Wang, Q., Raja, K.S., Janda, K.D., Lin, T.W., Finn, M.G., Blue fluorescent antibodies as reporters of steric accessibility in virus conjugates. Bioconjug. Chem. 14 (2003), 38–43.
234. [234] Lewis, J.D., Destito, G., Zijlstra, A., Gonzalez, M.J., Quigley, J.P., Manchester, M., Stuhlmann, H., Viral nanoparticles as tools for intravital vascular imaging. Nat. Med. 12 (2006), 354–360.
235. [235] Shukla, S., Ablack, A.L., Wen, A.M., Lee, K.L., Lewis, J.D., Steinmetz, N.F., Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle potato virus X. Mol. Pharm. 10 (2013), 33–42.
236. [236] Steinmetz, N.F., Manchester, M., PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo. Biomacromolecules 10 (2009), 784–792.
237. [237] Raja, K.S., Wang, Q., Gonzalez, M.J., Manchester, M., Johnson, J.E., Finn, M., Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 4 (2003), 472–476.
238. [238] Seim, K.L., Obermeyer, A.C., Francis, M.B., Oxidative modification of native protein residues using cerium(IV) ammonium nitrate. J. Am. Chem. Soc. 133 (2011), 16970–16976.
239. [239] Behrens, C.R., Hooker, J.M., Obermeyer, A.C., Romanini, D.W., Katz, E.M., Francis, M.B., Rapid chemoselective bioconjugation through oxidative coupling of anilines and aminophenols. J. Am. Chem. Soc. 133 (2011), 16398–16401.
240. [240] Yildiz, I., Tsvetkova, I., Wen, A.M., Shukla, S., Masarapu, M.H., Dragnea, B., Steinmetz, N.F., Engineering of Brome mosaic virus for biomedical applications. RSC Adv. 2 (2012), 3670–3677.
241. [241] Steinmetz, N.F., Mertens, M.E., Taurog, R.E., Johnson, J.E., Commandeur, U., Fischer, R., Manchester, M., Potato virus X as a novel platform for potential biomedical applications. Nano Lett. 10 (2010), 305–312.
242. [242] Vannucci, L., Falvo, E., Fornara, M., Di Micco, P., Benada, O., Krizan, J., Svoboda, J., Hulikova-Capkova, K., Morea, V., Boffi, A., Ceci, P., Selective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles. Int. J. Nanomedicine 7 (2012), 1489–1509.
243. [243] Falvo, E., Tremante, E., Arcovito, A., Papi, M., Elad, N., Boffi, A., Morea, V., Conti, G., Toffoli, G., Fracasso, G., Giacomini, P., Ceci, P., Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing PAS elements. Biomacromolecules, 2015, 10.1021/acs.biomac.5b01446.
244. [244] Kanekiyo, M., Wei, C.J., Yassine, H.M., McTamney, P.M., Boyington, J.C., Whittle, J.R., Rao, S.S., Kong, W.P., Wang, L., Nabel, G.J., Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499 (2013), 102–106.
245. [245] Richert, L.E., Servid, A.E., Harmsen, A.L., Rynda-Apple, A., Han, S., Wiley, J.A., Douglas, T., Harmsen, A.G., A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine 30 (2012), 3653–3665.
246. [246] Rynda-Apple, A., Dobrinen, E., McAlpine, M., Read, A., Harmsen, A., Richert, L.E., Calverley, M., Pallister, K., Voyich, J., Wiley, J.A., Virus-like particle-induced protection against MRSA pneumonia is dependent on IL-13 and enhancement of phagocyte function. Am. J. Pathol. 181 (2012), 196–210.